Talphera Inc
TLPH0.403USD
+0.000+0.02%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
6.88MValor de mercado
PerdaP/L TTM
Mais detalhes de Talphera Inc Empresa
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
Informações da empresa
Código da empresaTLPH
Nome da EmpresaTalphera Inc
Data de listagemFeb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
Número de funcionários13
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 11
Endereço1850 Gateway Drive
CidadeSAN MATEO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94404
Telefone16502163500
Sitehttps://talphera.com/
Código da empresaTLPH
Data de listagemFeb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
Dr. Stephen J. Hoffman, M.D., Ph.D.
Dr. Stephen J. Hoffman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: qua, 5 de mar
Moeda: USDAtualizado em: qua, 5 de mar
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
Distribuição de ações
Atualizado em: sex, 1 de ago
Atualizado em: sex, 1 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
Investidores
Investidores
Proporção
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
Tipos de investidores
Investidores
Proporção
Hedge Fund
25.46%
Investment Advisor
4.28%
Individual Investor
2.62%
Investment Advisor/Hedge Fund
1.06%
Research Firm
0.45%
Venture Capital
0.07%
Other
66.06%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
79
6.96M
33.93%
-504.17K
2025Q1
82
6.66M
34.60%
-832.94K
2024Q4
84
5.24M
30.79%
-2.31M
2024Q3
100
5.33M
31.39%
-2.35M
2024Q2
109
5.51M
32.40%
-2.29M
2024Q1
113
5.56M
32.76%
-881.00K
2023Q4
117
5.91M
35.12%
-445.19K
2023Q3
127
7.03M
43.10%
+3.84M
2023Q2
136
1.17M
10.69%
-920.00K
2023Q1
169
1.22M
11.24%
-974.29K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Rosalind Advisors, Inc.
2.00M
9.77%
+1.39M
+226.41%
Mar 31, 2025
Nantahala Capital Management, LLC
1.99M
9.72%
--
--
Apr 25, 2025
Armistice Capital LLC
890.35K
4.34%
-661.26K
-42.62%
Dec 31, 2023
Bleichroeder LP
426.62K
2.08%
+426.62K
--
Mar 31, 2025
Angotti Vincent J
367.85K
1.79%
+265.56K
+259.62%
Apr 25, 2025
Rock Springs Capital Management LP
316.46K
1.54%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
237.53K
1.16%
-3.44K
-1.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
165.61K
0.81%
+2.40K
+1.47%
Mar 31, 2025
Values First Advisors, Inc.
97.32K
0.47%
+771.00
+0.80%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
91.55K
0.45%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Data
Tipo
Proporção
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
